Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly
Emergent BioSolutions’ senior management team, headed by Fuad El-Hibri, chairman and chief executive officer and Daniel J. Abdun-Nabi, president and chief operating officer, are hosting “Bioterrorism Prevention, Preparedness and Response,” a forum uniquely organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA). The one-day event is an interactive discussion related to [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Hudson Institute, North Atlantic Treaty Organization · Tagged with: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Hudson Institute, NATO, North Atlantic Treaty Organization, United States, United States Department of Defense
Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense.
Company Preparing Response to DoD Request for Proposal for Delivery of Up to 14 Million Additional Doses of BioThrax
ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Departmentof Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax([R]) (Anthrax [...]
In: Uncategorized · Tagged with: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Federal government of the United States, Immunization, United States, United States Department of Defense, US government